The skin allergy risk assessment-integrated chemical environment (SARA-ICE) defined approach to derive points of departure for skin sensitization.

Mechanistically based non-animal methods for assessing skin sensitization hazard have been developed, but are not considered sufficient, individually, to conclusively define the skin sensitization potential or potency of a chemical. This resulted in the development of defined approaches (DAs), as documented in OECD TG 497, for combining information sources in a prescriptive manner to provide a determination of risk or potency. However, there are currently no DAs within OECD TG 497 that can derive a point of departure (POD) for risk assessment.

Barriers and Facilitators to Quality Healthcare for African Americans with Incarceration Histories.

Background: Prior research has shown that African American men and women are more likely to receive lower quality healthcare compared to their white counterparts, which is exacerbated in jail and prison healthcare systems.

Objective: The purpose of this study is to explore barriers and facilitators to quality healthcare among African American men and women released from Illinois State Prisons or Cook County Jail by examining their opinions and experiences with overall healthcare and cancer screening during and after incarceration.

Design: Four focus groups (n = 25 "co-researchers") were conducted to understand how formerly incarcerated African American men and women perceive and describe their experience of accessing, understanding, and utilizing healthcare during and after incarceration.

Insomnia Symptoms are Associated with Return to use and Non-fatal Overdose following Opioid Use Disorder Treatment.

Study Objectives: Opioid use disorder (OUD) is a chronic, relapse-prone condition, often accompanied by sleep disturbances such as insomnia. While sleep disturbances have been implicated in negative treatment outcomes, no large-scale studies have examined the relationship between insomnia disorder and outcomes for persons completing an acute OUD treatment episode. This study assessed the association between insomnia symptoms at treatment intake, during treatment, and following acute treatment with post-treatment episode return to use, and non-fatal overdose outcomes.